(COR) Cencora - Ratings and Ratios

Cencora, Inc. (NYSE: COR) operates as a global healthcare solutions provider, specializing in the sourcing and distribution of pharmaceutical products. The company serves a diverse range of customers, including acute care hospitals, retail pharmacies, and biotechnology manufacturers. Its U.S. Healthcare Solutions segment offers a comprehensive suite of services, including pharmaceutical distribution, pharmacy management, supply chain software, and clinical trial support. The segment also provides specialty products, such as injectable pharmaceuticals and vaccines, to healthcare providers. Additionally, Cencora serves the animal health market with products like vaccines and parasiticides, and offers data analytics and consulting services to pharmaceutical manufacturers.

The company’s International Healthcare Solutions segment focuses on global pharmaceutical wholesale and commercialization services. It distributes healthcare products to international markets, including pharmacies, hospitals, and health centers. The segment also provides specialty logistics services for the biopharmaceutical industry. Cencora, formerly known as AmerisourceBergen Corporation, has a long history dating back to 1871. Headquartered in Conshohocken, Pennsylvania, the company rebranded as Cencora, Inc. in August 2023, reflecting its strategic evolution in the healthcare sector.

3-Month Forecast: Based on and , Cencora, Inc. (NYSE: COR) is expected to maintain upward momentum in the near term. The stock is trading above its 20-day and 50-day moving averages, with the SMA20 at $277.67 and SMA50 at $262.11. The average true range (ATR) of $6.72 suggests moderate volatility. With a forward P/E of 18.55, the stock is positioned for potential earnings growth. However, the high current P/E of 40.33 and P/B of 243.09 indicate elevated valuations. Investors should monitor the company’s ability to meet earnings expectations and sustain its revenue growth trajectory.